

Global Oncogene Inhibitors Market Growth 2024-2030

<https://marketpublishers.com/r/GFA6699891A3EN.html>

Date: July 2024

Pages: 110

Price: US\$ 3,660.00 (Single User License)

ID: GFA6699891A3EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Oncogene Inhibitors market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the "Oncogene Inhibitors Industry Forecast" looks at past sales and reviews total world Oncogene Inhibitors sales in 2023, providing a comprehensive analysis by region and market sector of projected Oncogene Inhibitors sales for 2024 through 2030. With Oncogene Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Oncogene Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Oncogene Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oncogene Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Oncogene Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oncogene Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oncogene Inhibitors.

United States market for Oncogene Inhibitors is estimated to increase from US\$ million

in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Oncogene Inhibitors is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Oncogene Inhibitors is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Oncogene Inhibitors players cover AstraZeneca, Merck Sharp & Dohme, Pfizer, Celgene, Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Oncogene Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Oral

Injection

Segmentation by Application:

Cancer Treatment

Clinical Research

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

AstraZeneca

Merck Sharp & Dohme

Pfizer

Celgene

Novartis

Pacira BioSciences

Johnson & Johnson

Fresenius Kabi

Assertio

Takeda Pharmaceutical

Teva Pharmaceutical Industries

Cipla

Sun Pharmaceutical Industries

Shanghai Fosun Pharmaceutical

Ingenus

Key Questions Addressed in this Report

What is the 10-year outlook for the global Oncogene Inhibitors market?

What factors are driving Oncogene Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Oncogene Inhibitors market opportunities vary by end market size?

How does Oncogene Inhibitors break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Oncogene Inhibitors Annual Sales 2019-2030
 - 2.1.2 World Current & Future Analysis for Oncogene Inhibitors by Geographic Region, 2019, 2023 & 2030
 - 2.1.3 World Current & Future Analysis for Oncogene Inhibitors by Country/Region, 2019, 2023 & 2030
- 2.2 Oncogene Inhibitors Segment by Type
 - 2.2.1 Oral
 - 2.2.2 Injection
- 2.3 Oncogene Inhibitors Sales by Type
 - 2.3.1 Global Oncogene Inhibitors Sales Market Share by Type (2019-2024)
 - 2.3.2 Global Oncogene Inhibitors Revenue and Market Share by Type (2019-2024)
 - 2.3.3 Global Oncogene Inhibitors Sale Price by Type (2019-2024)
- 2.4 Oncogene Inhibitors Segment by Application
 - 2.4.1 Cancer Treatment
 - 2.4.2 Clinical Research
 - 2.4.3 Other
- 2.5 Oncogene Inhibitors Sales by Application
 - 2.5.1 Global Oncogene Inhibitors Sale Market Share by Application (2019-2024)
 - 2.5.2 Global Oncogene Inhibitors Revenue and Market Share by Application (2019-2024)
 - 2.5.3 Global Oncogene Inhibitors Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

- 3.1 Global Oncogene Inhibitors Breakdown Data by Company
 - 3.1.1 Global Oncogene Inhibitors Annual Sales by Company (2019-2024)
 - 3.1.2 Global Oncogene Inhibitors Sales Market Share by Company (2019-2024)
- 3.2 Global Oncogene Inhibitors Annual Revenue by Company (2019-2024)
 - 3.2.1 Global Oncogene Inhibitors Revenue by Company (2019-2024)
 - 3.2.2 Global Oncogene Inhibitors Revenue Market Share by Company (2019-2024)
- 3.3 Global Oncogene Inhibitors Sale Price by Company
- 3.4 Key Manufacturers Oncogene Inhibitors Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers Oncogene Inhibitors Product Location Distribution
 - 3.4.2 Players Oncogene Inhibitors Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
- 3.6 New Products and Potential Entrants
- 3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR ONCOGENE INHIBITORS BY GEOGRAPHIC REGION

- 4.1 World Historic Oncogene Inhibitors Market Size by Geographic Region (2019-2024)
 - 4.1.1 Global Oncogene Inhibitors Annual Sales by Geographic Region (2019-2024)
 - 4.1.2 Global Oncogene Inhibitors Annual Revenue by Geographic Region (2019-2024)
- 4.2 World Historic Oncogene Inhibitors Market Size by Country/Region (2019-2024)
 - 4.2.1 Global Oncogene Inhibitors Annual Sales by Country/Region (2019-2024)
 - 4.2.2 Global Oncogene Inhibitors Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Oncogene Inhibitors Sales Growth
- 4.4 APAC Oncogene Inhibitors Sales Growth
- 4.5 Europe Oncogene Inhibitors Sales Growth
- 4.6 Middle East & Africa Oncogene Inhibitors Sales Growth

5 AMERICAS

- 5.1 Americas Oncogene Inhibitors Sales by Country
 - 5.1.1 Americas Oncogene Inhibitors Sales by Country (2019-2024)
 - 5.1.2 Americas Oncogene Inhibitors Revenue by Country (2019-2024)
- 5.2 Americas Oncogene Inhibitors Sales by Type (2019-2024)
- 5.3 Americas Oncogene Inhibitors Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Oncogene Inhibitors Sales by Region

6.1.1 APAC Oncogene Inhibitors Sales by Region (2019-2024)

6.1.2 APAC Oncogene Inhibitors Revenue by Region (2019-2024)

6.2 APAC Oncogene Inhibitors Sales by Type (2019-2024)

6.3 APAC Oncogene Inhibitors Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Oncogene Inhibitors by Country

7.1.1 Europe Oncogene Inhibitors Sales by Country (2019-2024)

7.1.2 Europe Oncogene Inhibitors Revenue by Country (2019-2024)

7.2 Europe Oncogene Inhibitors Sales by Type (2019-2024)

7.3 Europe Oncogene Inhibitors Sales by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Oncogene Inhibitors by Country

8.1.1 Middle East & Africa Oncogene Inhibitors Sales by Country (2019-2024)

8.1.2 Middle East & Africa Oncogene Inhibitors Revenue by Country (2019-2024)

8.2 Middle East & Africa Oncogene Inhibitors Sales by Type (2019-2024)

8.3 Middle East & Africa Oncogene Inhibitors Sales by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Oncogene Inhibitors

10.3 Manufacturing Process Analysis of Oncogene Inhibitors

10.4 Industry Chain Structure of Oncogene Inhibitors

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Oncogene Inhibitors Distributors

11.3 Oncogene Inhibitors Customer

12 WORLD FORECAST REVIEW FOR ONCOGENE INHIBITORS BY GEOGRAPHIC REGION

12.1 Global Oncogene Inhibitors Market Size Forecast by Region

12.1.1 Global Oncogene Inhibitors Forecast by Region (2025-2030)

12.1.2 Global Oncogene Inhibitors Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country (2025-2030)

12.3 APAC Forecast by Region (2025-2030)

12.4 Europe Forecast by Country (2025-2030)

12.5 Middle East & Africa Forecast by Country (2025-2030)

12.6 Global Oncogene Inhibitors Forecast by Type (2025-2030)

12.7 Global Oncogene Inhibitors Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

13.1 AstraZeneca

13.1.1 AstraZeneca Company Information

13.1.2 AstraZeneca Oncogene Inhibitors Product Portfolios and Specifications

13.1.3 AstraZeneca Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 AstraZeneca Main Business Overview

13.1.5 AstraZeneca Latest Developments

13.2 Merck Sharp & Dohme

13.2.1 Merck Sharp & Dohme Company Information

13.2.2 Merck Sharp & Dohme Oncogene Inhibitors Product Portfolios and Specifications

13.2.3 Merck Sharp & Dohme Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.2.4 Merck Sharp & Dohme Main Business Overview

13.2.5 Merck Sharp & Dohme Latest Developments

13.3 Pfizer

13.3.1 Pfizer Company Information

13.3.2 Pfizer Oncogene Inhibitors Product Portfolios and Specifications

13.3.3 Pfizer Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.3.4 Pfizer Main Business Overview

13.3.5 Pfizer Latest Developments

13.4 Celgene

13.4.1 Celgene Company Information

13.4.2 Celgene Oncogene Inhibitors Product Portfolios and Specifications

13.4.3 Celgene Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.4.4 Celgene Main Business Overview

13.4.5 Celgene Latest Developments

13.5 Novartis

13.5.1 Novartis Company Information

13.5.2 Novartis Oncogene Inhibitors Product Portfolios and Specifications

13.5.3 Novartis Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.5.4 Novartis Main Business Overview

- 13.5.5 Novartis Latest Developments
- 13.6 Pacira BioSciences
 - 13.6.1 Pacira BioSciences Company Information
 - 13.6.2 Pacira BioSciences Oncogene Inhibitors Product Portfolios and Specifications
 - 13.6.3 Pacira BioSciences Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.6.4 Pacira BioSciences Main Business Overview
 - 13.6.5 Pacira BioSciences Latest Developments
- 13.7 Johnson & Johnson
 - 13.7.1 Johnson & Johnson Company Information
 - 13.7.2 Johnson & Johnson Oncogene Inhibitors Product Portfolios and Specifications
 - 13.7.3 Johnson & Johnson Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.7.4 Johnson & Johnson Main Business Overview
 - 13.7.5 Johnson & Johnson Latest Developments
- 13.8 Fresenius Kabi
 - 13.8.1 Fresenius Kabi Company Information
 - 13.8.2 Fresenius Kabi Oncogene Inhibitors Product Portfolios and Specifications
 - 13.8.3 Fresenius Kabi Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.8.4 Fresenius Kabi Main Business Overview
 - 13.8.5 Fresenius Kabi Latest Developments
- 13.9 Assertio
 - 13.9.1 Assertio Company Information
 - 13.9.2 Assertio Oncogene Inhibitors Product Portfolios and Specifications
 - 13.9.3 Assertio Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.9.4 Assertio Main Business Overview
 - 13.9.5 Assertio Latest Developments
- 13.10 Takeda Pharmaceutical
 - 13.10.1 Takeda Pharmaceutical Company Information
 - 13.10.2 Takeda Pharmaceutical Oncogene Inhibitors Product Portfolios and Specifications
 - 13.10.3 Takeda Pharmaceutical Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.10.4 Takeda Pharmaceutical Main Business Overview
 - 13.10.5 Takeda Pharmaceutical Latest Developments
- 13.11 Teva Pharmaceutical Industries
 - 13.11.1 Teva Pharmaceutical Industries Company Information

13.11.2 Teva Pharmaceutical Industries Oncogene Inhibitors Product Portfolios and Specifications

13.11.3 Teva Pharmaceutical Industries Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.11.4 Teva Pharmaceutical Industries Main Business Overview

13.11.5 Teva Pharmaceutical Industries Latest Developments

13.12 Cipla

13.12.1 Cipla Company Information

13.12.2 Cipla Oncogene Inhibitors Product Portfolios and Specifications

13.12.3 Cipla Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.12.4 Cipla Main Business Overview

13.12.5 Cipla Latest Developments

13.13 Sun Pharmaceutical Industries

13.13.1 Sun Pharmaceutical Industries Company Information

13.13.2 Sun Pharmaceutical Industries Oncogene Inhibitors Product Portfolios and Specifications

13.13.3 Sun Pharmaceutical Industries Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.13.4 Sun Pharmaceutical Industries Main Business Overview

13.13.5 Sun Pharmaceutical Industries Latest Developments

13.14 Shanghai Fosun Pharmaceutical

13.14.1 Shanghai Fosun Pharmaceutical Company Information

13.14.2 Shanghai Fosun Pharmaceutical Oncogene Inhibitors Product Portfolios and Specifications

13.14.3 Shanghai Fosun Pharmaceutical Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.14.4 Shanghai Fosun Pharmaceutical Main Business Overview

13.14.5 Shanghai Fosun Pharmaceutical Latest Developments

13.15 Ingenus

13.15.1 Ingenus Company Information

13.15.2 Ingenus Oncogene Inhibitors Product Portfolios and Specifications

13.15.3 Ingenus Oncogene Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.15.4 Ingenus Main Business Overview

13.15.5 Ingenus Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Oncogene Inhibitors Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Oncogene Inhibitors Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Oral

Table 4. Major Players of Injection

Table 5. Global Oncogene Inhibitors Sales by Type (2019-2024) & (K Units)

Table 6. Global Oncogene Inhibitors Sales Market Share by Type (2019-2024)

Table 7. Global Oncogene Inhibitors Revenue by Type (2019-2024) & (\$ million)

Table 8. Global Oncogene Inhibitors Revenue Market Share by Type (2019-2024)

Table 9. Global Oncogene Inhibitors Sale Price by Type (2019-2024) & (US\$/Unit)

Table 10. Global Oncogene Inhibitors Sale by Application (2019-2024) & (K Units)

Table 11. Global Oncogene Inhibitors Sale Market Share by Application (2019-2024)

Table 12. Global Oncogene Inhibitors Revenue by Application (2019-2024) & (\$ million)

Table 13. Global Oncogene Inhibitors Revenue Market Share by Application (2019-2024)

Table 14. Global Oncogene Inhibitors Sale Price by Application (2019-2024) & (US\$/Unit)

Table 15. Global Oncogene Inhibitors Sales by Company (2019-2024) & (K Units)

Table 16. Global Oncogene Inhibitors Sales Market Share by Company (2019-2024)

Table 17. Global Oncogene Inhibitors Revenue by Company (2019-2024) & (\$ millions)

Table 18. Global Oncogene Inhibitors Revenue Market Share by Company (2019-2024)

Table 19. Global Oncogene Inhibitors Sale Price by Company (2019-2024) & (US\$/Unit)

Table 20. Key Manufacturers Oncogene Inhibitors Producing Area Distribution and Sales Area

Table 21. Players Oncogene Inhibitors Products Offered

Table 22. Oncogene Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 23. New Products and Potential Entrants

Table 24. Market M&A Activity & Strategy

Table 25. Global Oncogene Inhibitors Sales by Geographic Region (2019-2024) & (K Units)

Table 26. Global Oncogene Inhibitors Sales Market Share Geographic Region (2019-2024)

Table 27. Global Oncogene Inhibitors Revenue by Geographic Region (2019-2024) & (\$

millions)

Table 28. Global Oncogene Inhibitors Revenue Market Share by Geographic Region (2019-2024)

Table 29. Global Oncogene Inhibitors Sales by Country/Region (2019-2024) & (K Units)

Table 30. Global Oncogene Inhibitors Sales Market Share by Country/Region (2019-2024)

Table 31. Global Oncogene Inhibitors Revenue by Country/Region (2019-2024) & (\$ millions)

Table 32. Global Oncogene Inhibitors Revenue Market Share by Country/Region (2019-2024)

Table 33. Americas Oncogene Inhibitors Sales by Country (2019-2024) & (K Units)

Table 34. Americas Oncogene Inhibitors Sales Market Share by Country (2019-2024)

Table 35. Americas Oncogene Inhibitors Revenue by Country (2019-2024) & (\$ millions)

Table 36. Americas Oncogene Inhibitors Sales by Type (2019-2024) & (K Units)

Table 37. Americas Oncogene Inhibitors Sales by Application (2019-2024) & (K Units)

Table 38. APAC Oncogene Inhibitors Sales by Region (2019-2024) & (K Units)

Table 39. APAC Oncogene Inhibitors Sales Market Share by Region (2019-2024)

Table 40. APAC Oncogene Inhibitors Revenue by Region (2019-2024) & (\$ millions)

Table 41. APAC Oncogene Inhibitors Sales by Type (2019-2024) & (K Units)

Table 42. APAC Oncogene Inhibitors Sales by Application (2019-2024) & (K Units)

Table 43. Europe Oncogene Inhibitors Sales by Country (2019-2024) & (K Units)

Table 44. Europe Oncogene Inhibitors Revenue by Country (2019-2024) & (\$ millions)

Table 45. Europe Oncogene Inhibitors Sales by Type (2019-2024) & (K Units)

Table 46. Europe Oncogene Inhibitors Sales by Application (2019-2024) & (K Units)

Table 47. Middle East & Africa Oncogene Inhibitors Sales by Country (2019-2024) & (K Units)

Table 48. Middle East & Africa Oncogene Inhibitors Revenue Market Share by Country (2019-2024)

Table 49. Middle East & Africa Oncogene Inhibitors Sales by Type (2019-2024) & (K Units)

Table 50. Middle East & Africa Oncogene Inhibitors Sales by Application (2019-2024) & (K Units)

Table 51. Key Market Drivers & Growth Opportunities of Oncogene Inhibitors

Table 52. Key Market Challenges & Risks of Oncogene Inhibitors

Table 53. Key Industry Trends of Oncogene Inhibitors

Table 54. Oncogene Inhibitors Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56. Oncogene Inhibitors Distributors List

Table 57. Oncogene Inhibitors Customer List

Table 58. Global Oncogene Inhibitors Sales Forecast by Region (2025-2030) & (K Units)

Table 59. Global Oncogene Inhibitors Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 60. Americas Oncogene Inhibitors Sales Forecast by Country (2025-2030) & (K Units)

Table 61. Americas Oncogene Inhibitors Annual Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 62. APAC Oncogene Inhibitors Sales Forecast by Region (2025-2030) & (K Units)

Table 63. APAC Oncogene Inhibitors Annual Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 64. Europe Oncogene Inhibitors Sales Forecast by Country (2025-2030) & (K Units)

Table 65. Europe Oncogene Inhibitors Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 66. Middle East & Africa Oncogene Inhibitors Sales Forecast by Country (2025-2030) & (K Units)

Table 67. Middle East & Africa Oncogene Inhibitors Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 68. Global Oncogene Inhibitors Sales Forecast by Type (2025-2030) & (K Units)

Table 69. Global Oncogene Inhibitors Revenue Forecast by Type (2025-2030) & (\$ millions)

Table 70. Global Oncogene Inhibitors Sales Forecast by Application (2025-2030) & (K Units)

Table 71. Global Oncogene Inhibitors Revenue Forecast by Application (2025-2030) & (\$ millions)

Table 72. AstraZeneca Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 73. AstraZeneca Oncogene Inhibitors Product Portfolios and Specifications

Table 74. AstraZeneca Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 75. AstraZeneca Main Business

Table 76. AstraZeneca Latest Developments

Table 77. Merck Sharp & Dohme Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 78. Merck Sharp & Dohme Oncogene Inhibitors Product Portfolios and Specifications

Table 79. Merck Sharp & Dohme Oncogene Inhibitors Sales (K Units), Revenue (\$

Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 80. Merck Sharp & Dohme Main Business

Table 81. Merck Sharp & Dohme Latest Developments

Table 82. Pfizer Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 83. Pfizer Oncogene Inhibitors Product Portfolios and Specifications

Table 84. Pfizer Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 85. Pfizer Main Business

Table 86. Pfizer Latest Developments

Table 87. Celgene Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 88. Celgene Oncogene Inhibitors Product Portfolios and Specifications

Table 89. Celgene Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 90. Celgene Main Business

Table 91. Celgene Latest Developments

Table 92. Novartis Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 93. Novartis Oncogene Inhibitors Product Portfolios and Specifications

Table 94. Novartis Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 95. Novartis Main Business

Table 96. Novartis Latest Developments

Table 97. Pacira BioSciences Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 98. Pacira BioSciences Oncogene Inhibitors Product Portfolios and Specifications

Table 99. Pacira BioSciences Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 100. Pacira BioSciences Main Business

Table 101. Pacira BioSciences Latest Developments

Table 102. Johnson & Johnson Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 103. Johnson & Johnson Oncogene Inhibitors Product Portfolios and Specifications

Table 104. Johnson & Johnson Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 105. Johnson & Johnson Main Business

Table 106. Johnson & Johnson Latest Developments

Table 107. Fresenius Kabi Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 108. Fresenius Kabi Oncogene Inhibitors Product Portfolios and Specifications

Table 109. Fresenius Kabi Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 110. Fresenius Kabi Main Business

Table 111. Fresenius Kabi Latest Developments

Table 112. Assertio Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 113. Assertio Oncogene Inhibitors Product Portfolios and Specifications

Table 114. Assertio Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 115. Assertio Main Business

Table 116. Assertio Latest Developments

Table 117. Takeda Pharmaceutical Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 118. Takeda Pharmaceutical Oncogene Inhibitors Product Portfolios and Specifications

Table 119. Takeda Pharmaceutical Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 120. Takeda Pharmaceutical Main Business

Table 121. Takeda Pharmaceutical Latest Developments

Table 122. Teva Pharmaceutical Industries Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 123. Teva Pharmaceutical Industries Oncogene Inhibitors Product Portfolios and Specifications

Table 124. Teva Pharmaceutical Industries Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 125. Teva Pharmaceutical Industries Main Business

Table 126. Teva Pharmaceutical Industries Latest Developments

Table 127. Cipla Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 128. Cipla Oncogene Inhibitors Product Portfolios and Specifications

Table 129. Cipla Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 130. Cipla Main Business

Table 131. Cipla Latest Developments

Table 132. Sun Pharmaceutical Industries Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 133. Sun Pharmaceutical Industries Oncogene Inhibitors Product Portfolios and Specifications

Table 134. Sun Pharmaceutical Industries Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 135. Sun Pharmaceutical Industries Main Business

Table 136. Sun Pharmaceutical Industries Latest Developments

Table 137. Shanghai Fosun Pharmaceutical Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 138. Shanghai Fosun Pharmaceutical Oncogene Inhibitors Product Portfolios and Specifications

Table 139. Shanghai Fosun Pharmaceutical Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 140. Shanghai Fosun Pharmaceutical Main Business

Table 141. Shanghai Fosun Pharmaceutical Latest Developments

Table 142. Ingenus Basic Information, Oncogene Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 143. Ingenus Oncogene Inhibitors Product Portfolios and Specifications

Table 144. Ingenus Oncogene Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 145. Ingenus Main Business

Table 146. Ingenus Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Oncogene Inhibitors
- Figure 2. Oncogene Inhibitors Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Oncogene Inhibitors Sales Growth Rate 2019-2030 (K Units)
- Figure 7. Global Oncogene Inhibitors Revenue Growth Rate 2019-2030 (\$ millions)
- Figure 8. Oncogene Inhibitors Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Figure 9. Oncogene Inhibitors Sales Market Share by Country/Region (2023)
- Figure 10. Oncogene Inhibitors Sales Market Share by Country/Region (2019, 2023 & 2030)
- Figure 11. Product Picture of Oral
- Figure 12. Product Picture of Injection
- Figure 13. Global Oncogene Inhibitors Sales Market Share by Type in 2023
- Figure 14. Global Oncogene Inhibitors Revenue Market Share by Type (2019-2024)
- Figure 15. Oncogene Inhibitors Consumed in Cancer Treatment
- Figure 16. Global Oncogene Inhibitors Market: Cancer Treatment (2019-2024) & (K Units)
- Figure 17. Oncogene Inhibitors Consumed in Clinical Research
- Figure 18. Global Oncogene Inhibitors Market: Clinical Research (2019-2024) & (K Units)
- Figure 19. Oncogene Inhibitors Consumed in Other
- Figure 20. Global Oncogene Inhibitors Market: Other (2019-2024) & (K Units)
- Figure 21. Global Oncogene Inhibitors Sale Market Share by Application (2023)
- Figure 22. Global Oncogene Inhibitors Revenue Market Share by Application in 2023
- Figure 23. Oncogene Inhibitors Sales by Company in 2023 (K Units)
- Figure 24. Global Oncogene Inhibitors Sales Market Share by Company in 2023
- Figure 25. Oncogene Inhibitors Revenue by Company in 2023 (\$ millions)
- Figure 26. Global Oncogene Inhibitors Revenue Market Share by Company in 2023
- Figure 27. Global Oncogene Inhibitors Sales Market Share by Geographic Region (2019-2024)
- Figure 28. Global Oncogene Inhibitors Revenue Market Share by Geographic Region in 2023
- Figure 29. Americas Oncogene Inhibitors Sales 2019-2024 (K Units)

- Figure 30. Americas Oncogene Inhibitors Revenue 2019-2024 (\$ millions)
- Figure 31. APAC Oncogene Inhibitors Sales 2019-2024 (K Units)
- Figure 32. APAC Oncogene Inhibitors Revenue 2019-2024 (\$ millions)
- Figure 33. Europe Oncogene Inhibitors Sales 2019-2024 (K Units)
- Figure 34. Europe Oncogene Inhibitors Revenue 2019-2024 (\$ millions)
- Figure 35. Middle East & Africa Oncogene Inhibitors Sales 2019-2024 (K Units)
- Figure 36. Middle East & Africa Oncogene Inhibitors Revenue 2019-2024 (\$ millions)
- Figure 37. Americas Oncogene Inhibitors Sales Market Share by Country in 2023
- Figure 38. Americas Oncogene Inhibitors Revenue Market Share by Country (2019-2024)
- Figure 39. Americas Oncogene Inhibitors Sales Market Share by Type (2019-2024)
- Figure 40. Americas Oncogene Inhibitors Sales Market Share by Application (2019-2024)
- Figure 41. United States Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 42. Canada Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 43. Mexico Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 44. Brazil Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 45. APAC Oncogene Inhibitors Sales Market Share by Region in 2023
- Figure 46. APAC Oncogene Inhibitors Revenue Market Share by Region (2019-2024)
- Figure 47. APAC Oncogene Inhibitors Sales Market Share by Type (2019-2024)
- Figure 48. APAC Oncogene Inhibitors Sales Market Share by Application (2019-2024)
- Figure 49. China Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 50. Japan Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 51. South Korea Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 52. Southeast Asia Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 53. India Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 54. Australia Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 55. China Taiwan Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 56. Europe Oncogene Inhibitors Sales Market Share by Country in 2023
- Figure 57. Europe Oncogene Inhibitors Revenue Market Share by Country (2019-2024)
- Figure 58. Europe Oncogene Inhibitors Sales Market Share by Type (2019-2024)
- Figure 59. Europe Oncogene Inhibitors Sales Market Share by Application (2019-2024)
- Figure 60. Germany Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 61. France Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 62. UK Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 63. Italy Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 64. Russia Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)
- Figure 65. Middle East & Africa Oncogene Inhibitors Sales Market Share by Country (2019-2024)

Figure 66. Middle East & Africa Oncogene Inhibitors Sales Market Share by Type (2019-2024)

Figure 67. Middle East & Africa Oncogene Inhibitors Sales Market Share by Application (2019-2024)

Figure 68. Egypt Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 69. South Africa Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 70. Israel Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 71. Turkey Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 72. GCC Countries Oncogene Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 73. Manufacturing Cost Structure Analysis of Oncogene Inhibitors in 2023

Figure 74. Manufacturing Process Analysis of Oncogene Inhibitors

Figure 75. Industry Chain Structure of Oncogene Inhibitors

Figure 76. Channels of Distribution

Figure 77. Global Oncogene Inhibitors Sales Market Forecast by Region (2025-2030)

Figure 78. Global Oncogene Inhibitors Revenue Market Share Forecast by Region (2025-2030)

Figure 79. Global Oncogene Inhibitors Sales Market Share Forecast by Type (2025-2030)

Figure 80. Global Oncogene Inhibitors Revenue Market Share Forecast by Type (2025-2030)

Figure 81. Global Oncogene Inhibitors Sales Market Share Forecast by Application (2025-2030)

Figure 82. Global Oncogene Inhibitors Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Oncogene Inhibitors Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/GFA6699891A3EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFA6699891A3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970